New drug combo trial aims to shrink tough stomach cancers
NCT ID NCT06846346
Summary
This study is testing whether adding a new drug called ivonescimab to standard chemotherapy helps shrink tumors better in people with advanced stomach or esophageal cancer. It will enroll 88 adults whose cancer has spread or cannot be removed by surgery. The main goal is to see if the combination leads to more tumor shrinkage compared to what is expected with chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Léon Bérard
RECRUITINGLyon, 69008, France
Contact
-
Institut Jean Godinot
RECRUITINGReims, 51100, France
Contact
-
Institut Paoli Calmettes
NOT_YET_RECRUITINGMarseille, France
Contact
-
Institut de Cancerologie de l'Ouest - Site René Gauducheau
NOT_YET_RECRUITINGSaint-Herblain, France
Contact
Conditions
Explore the condition pages connected to this study.